45 results about "Benign lesion" patented technology

The present invention provides a method and a kit for determining whether a head and neck cancer is HPV-related. In one embodiment, an RNAscope® HPV assay was designed to detect the presence of E6 / E7 mRNA of certain high-risk HPV subtypes related to head and neck cancer. The present invention also provides a method and a kit for determining whether a cervical lesion is a benign lesion or a cervical intraepithethial neoplasm lesion. The present invention further provides a method for determining the progression of cervical intraepithethial neoplasm based on the spatial pattern and levels of the E6 / E7 mRNA of certain high-risk HPV subtypes. The present invention also provides a method for determining the risk of developing cervical cancer in a human diagnosed with cervical intraepithethial neoplasm based on presence and absence of the certain subgroups of high-risk HPV subtypes.

The present invention discloses a method and an apparatus for identifying a pathological picture. The method comprises: obtaining sample data, wherein the sample data comprises a positive sample and anegative sample, the positive sample is a malignant lesion pathological picture, the negative sample is a normal or a benign lesion pathological picture, and a lesion area is marked on the malignantlesion pathological picture; dividing the sample data into a training set and a test set; training a deep neural network model by using the training set; testing the trained deep neural network modelby using the test set; performing parameter adjustment on the trained deep neural network model according to a test result; and identifying the pathological picture by using the trained deep neural network model. According to the method and apparatus disclosed by the present invention, the efficiency and accuracy of pathological picture identification can be improved.

A computer-aided diagnosis (CAD) scheme to aid in the detection, characterization, diagnosis, and / or assessment of normal and diseased states (including lesions and / or images). The scheme employs lesion features for characterizing the lesion and includes non-parametric classification, to aid in the development of CAD methods in a limited database scenario to distinguish between malignant and benign lesions. The non-parametric classification is robust to kernel size.

Robust classification methods analyze magnetic resonance spectroscopy (MRS) data (spectra) of fine needle aspirates taken from breast tumors. The resultant data when compared with the histopathology and clinical criteria provide computerized classification-based diagnosis and prognosis with a very high degree of accuracy and reliability. Diagnostic correlation performed between the spectra and standard synoptic pathology findings contain detail regarding the pathology (malignant versus benign), vascular invasion by the primary cancer and lymph node involvement of the excised axillary lymph nodes. The classification strategy consisted of three stages: pre-processing of MR magnitude spectra to identify optimal spectral regions, cross-validated Linear Discriminant Analysis, and classification aggregation via Computerised Consensus Diagnosis. Malignant tissue was distinguished from benign lesions with an overall accuracy of 93%. From the same spectrum, lymph node involvement was predicted with an accuracy of 95% and tumor vascularisation with an overall accuracy of 92%.

The invention relates to a 2-(1-n-hexyloxy)ethylchlorin f salt, and a pharmaceutical composition and an application thereof. Specifically, the invention relates to the 2-(1-n-hexyloxy)ethylchlorin f salt used in photo-dynamic therapy and / or sono-dynamic therapy. The salt is soluble in water, and has stable properties. The salt can be used as a photosensitizer and / or a sound-sensitizer. The salt is suitable to be used for treating and diagnosing relatively large malignant, precancerous lesions or benign lesions. The invention also relates to a pharmaceutical composition comprising the novel compound, and the application and a preparation method of the novel compound.

A method for selectively heating cancerous conditions of the breast including invasive ductal carcinoma and invasive glandular lobular carcinoma, and pre-cancerous conditions of the breast including ductal carcinoma in-situ, lobular carcinoma in-situ, and intraductal hyperplasia, as well as benign lesions (any localized pathological change in the breast tissue) such as fibroadenomas and cysts by irradiation of the breast tissue with adaptive phased array focused microwave energy is introduced. Microwave energy provides preferential heating of high-water content breast tissues such as carcinomas, fibroadenomas, and cysts compared to the surrounding lower-water content normal breast tissues. To focus the microwave energy in the breast, the patient's breast can be compressed and a single electric-field probe, inserted in the central portion of the breast, or two noninvasive electric-field probes on opposite sides of the breast skin, can be used to measure a feedback signal to adjust the microwave phase delivered to waveguide applicators on opposite sides of the compressed breast tissue. The initial microwave power delivered to the microwave applicators is set to a desired value that is known to produce a desired increase in temperature in breast tumors. Temperature feedback sensors are used to measure skin temperatures during treatment to adjust the microwave power delivered to the waveguide applicators to avoid overheating the skin. The microwave energy delivered to the waveguide applicators is monitored in real time during treatment, and the treatment is completed when a desired total microwave energy dose has been administered. By heating and destroying the breast lesion sufficiently, lesions can be reduced in size and surrounding normal breast tissues are spared so that surgical mastectomy can be replaced with surgical lumpectomy or the lesions can be completely destroyed so that surgical mastectomy or lumpectomy is avoided.

Compositions and methods are disclosed for evaluating a subject's vasculature integrity, for differentiating between a malignant lesion and a benign lesion, for evaluating the accessibility of a tumor to nano-sized therapeutics, for treating tumors, and for live or real time monitoring of a nano-probe's biodistribution.

The invention provides a kit for benign lesion identification and malignant lesion detection of the oral mucosa and a detection method thereof. The detection method comprises the following steps that 1, oral cavity examination is performed, and detailed information of lesions is recorded; 2, the mouth is rinsed with clean water to remove food debris; 3, a preexamination reagent is taken for gargling for 1-5 minutes; 4, a first examination reagent is taken in a dipping mode with a cotton swab to be embrocated on the partial lesions, and dyeing is performed for 2-10 minutes; 5, a second examination reagent is taken for gargling for 1-5 minutes; 6, semi-quantitative or quantitative evaluation is performed on the dyeing results by comparing the dyeing results with a color plate or a self-excitated fluorescence detecting instrument. The kit can be used for auxiliary differential diagnosis of the benign lesion and the malignant lesion of the oral mucosa and can assist a clinician to early diagnose an oral cavity cancer and monitor the malignant process of the oral precancerous lesions.

The present invention provides a method and a kit for determining whether a head and neck cancer is HPV-related. In one embodiment, an RNAscope (TM) HPV assay was designed to detect the presence of E6 / E7 mRNA of certain high-risk HPV subtypes related to head and neck cancer. The present invention also provides a method and a kit for determining whether a cervical lesion is a benign lesion or a cervical intraepithethial neoplasm lesion. In one embodiment, an RNAscope (TM) HPV assay was designed to detect the presence of E6 / E7 mRNA of certain high-risk HPV subtypes related to cervical cancer. The present invention further provides a method for determining the progression of cervical intraepithethial neoplasm based on the spatial pattern and levels of the E6 / E7 mRNA of certain high-risk HPV subtypes. The present invention also provides a method for determining the risk of developing cervical cancer in a human diagnosed with cervical intraepithethial neoplasm based on presence and absence of the certain subgroups of high-risk HPV subtypes.

The invention provides a kit for benign lesion identification and malignant lesion detection of the oral mucosa and a detection method thereof. The detection method comprises the following steps that 1, oral cavity examination is performed, and detailed information of lesions is recorded; 2, the mouth is rinsed with clean water to remove food debris; 3, a preexamination reagent is taken for gargling for 1-5 minutes; 4, a first examination reagent is taken in a dipping mode with a cotton swab to be embrocated on the partial lesions, and dyeing is performed for 2-10 minutes; 5, a second examination reagent is taken for gargling for 1-5 minutes; 6, semi-quantitative or quantitative evaluation is performed on the dyeing results by comparing the dyeing results with a color plate or a self-excitated fluorescence detecting instrument. The kit can be used for auxiliary differential diagnosis of the benign lesion and the malignant lesion of the oral mucosa and can assist a clinician to early diagnose an oral cavity cancer and monitor the malignant process of the oral precancerous lesions.

A method for treating cancerous or benign conditions of a body or organ employs selective irradiation of the body tissue with energy. The method includes the steps of monitoring temperatures of the skin surface adjacent the body, positioining at least one energy applicator around the body, delivering energy to the at least one energy applicator to selectively irradiate the body tissue with energy and treat at least one of cancerous and benign conditions of the body, adjusting the level of power to be delivered to the at least one energy applicator during treatment based on the monitored skin temperatures, monitoring the energy delivered to the at least one energy applicator, determining total energy delivered to the at least one energy applicator, and completing the treatment when the desired total energy dose has been delivered by the at least one energy applicator to the body.

The invention provides a system and method for multiple classification of breast ultrasound images based on cross-correlation features, including an ultrasound image preprocessing unit; a region of interest extraction unit for extracting images of the region of interest; an internal cross-correlation density feature extraction unit for extracting sense The internal cross-correlation density eigenvalue of the image of interest; the traditional feature extraction unit is used to extract a variety of traditional eigenvalues ​​of the image of the region of interest; the multi-class classification unit is used to train the classifier and convert the internal cross-correlation density eigenvalue vector The traditional feature vectors are input to the three trained classifiers for classification, and the most predicted category is taken as the final classification result. The classification method of the present invention increases the feature based on the internal cross-correlation density of the region of interest, can effectively improve the effect of breast ultrasound computer-aided diagnosis, and increases the classification category of breast cysts, a benign lesion, and further satisfies doctors' requirements for breast ultrasound computer-aided systems. demand.

The invention discloses a use of a Kin17 gene or protein in preparation of cervical cancer diagnosis and treatment medicaments. The inventor discoveries that an expression level of the Kin17 protein in normal cervical epithelial tissue and cervical benign lesion tissue cells is low but the expression level is high in cervical cancer tissue and thus the Kin17 protein keeps rapid proliferation activity of cervical cancer cells, is closely related to pathological parameters, chemotherapeutic effects and disease progress and has an important effect in cervical cancer generation and development. Through silencing of Kin17 expression in cervical cancer cells, cancer cell proliferation activity is inhibited and cervical cancer cell sensitivity to chemotherapeutic drugs is improved. The Kin17 gene or protein can be used as a novel cervical cancer diagnosis marker and medicament target. The Kin17 gene or protein can be used for cervical cancer early-identification diagnosis, patient prognosis evaluation and clinical treatment.

The invention discloses an artificial intelligence medical imaging system for auxiliary diagnosis of tumor malignant risk stratification, comprising: a data acquisition module, a data preprocessing module, a model establishment module, a model verification and optimization module, a hierarchical diagnosis module and a database platform. The auxiliary diagnosis system for tumor malignant risk stratification of the present invention is based on artificial intelligence technology, which can realize successive stratification of malignant risk of tumors, simulate clinical diagnosis ideas, and detect benign lesions and malignant tumors with high precision using artificial intelligence models The ability to automatically diagnose space-occupying lesions with clear imaging features can substantially assist clinical management decision-making of space-occupying lesions, improve the existing workflow of clinical diagnosis, increase physicians' confidence in diagnosis, reduce work pressure, and reduce the risk of low malignancy The anxiety of patients with lesions has greatly improved the diagnosis rate of benign lesions and malignant tumors, and it is expected to realize the implementation of artificial intelligence clinical auxiliary diagnosis.

The invention discloses a serum miRNA combination for thyroid tumor diagnosis and 131 iodine treatment and prognosis. The application of the substance for detecting miRNA in preparation of a product with any one of the following functions: diagnosing thyroid cancer, screening thyroid cancer, distinguishing thyroid cancer from thyroid benign lesion, distinguishing thyroid cancer from healthy people, evaluating prognosis conditions of thyroid cancer patients after 131 iodine treatment, and predicting survival conditions of the thyroid cancer patients after 131 iodine treatment. The miRNA is Has-miR-378d, Has-miR-130b-5p, and / or Has-miR-548j-3p, and the miRNA is characterized in that: Has-miR-378d, Has-miR-130b According to the serum miRNA marker explored by the invention, rapid early diagnosis of thyroid cancer and prejudgment of 131I treatment effect and survival prognosis condition can be realized, so that clinical doctors are guided to provide prevention and treatment schemes for patients.